Close Menu

NEW YORK – A woman with recurrent ovarian cancer has experienced a prolonged response to the PARP inhibitor olaparib that could be due to her full BRCA1 gene deletion.

The US Food and Drug Administration approved olaparib (AstraZeneca's Lynparza) in 2014 to treat advanced ovarian cancer patients with BRCA1 or BRCA2 mutations.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.